• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Treatment of chronic total occlusion with percutaneous coronary intervention is associated with improved survival as compared to medical treatment alone: insights from a single-centre registry
Rev Cardiovasc Med. 2021 Dec 22;22(4):1629-1632. doi: 10.31083/j.rcm2204169.ABSTRACTSymptom relief is currently the main indication to perform percutaneous coronary intervention (PCI) of chronic total occlusion (CTO). So far, none of the randomized trials for CTO treatment have demonstrated improved survival after PCI compared to optimal medical treatment (OMT) alone. We investigated whether CTO PCI in addition to OMT could improve survival over OMT alone. Data of 1004 patients with a treated CTO was analysed. Patients with acute coronary syndrome and who underwent coronary artery bypass graft surgery (CABG) were excluded,...
Source: Reviews in Cardiovascular Medicine - December 27, 2021 Category: Cardiology Authors: Povilas Budrys Vilhelmas Bajoras Michael Rees Ieva Marija Saule Giedrius Davidavicius Andrius Berukstis Arvydas Baranauskas Source Type: research

Coronary artery bypass graft surgery versus percutaneous coronary intervention in unprotected left main coronary artery disease: A systematic review.
Authors: Macovei L, Magopet R, Tanasa A, Raileanu C, Prisacariu C, Presura MR, Balasanian MO Abstract Critical lesion of the unprotected left main coronary disease carries a tremendous mortality burden, often associated with a diabetes status or multivessel disease, with coronary artery bypass grafting being the standard treatment for over 40 years. Percutaneous coronary intervention with drug eluting stents should be taken into consideration and could be a better option for patients with low SYNTAX score as validated by the recently published studies. This review summarizes the major randomized clinical trials and...
Source: Reviews in Cardiovascular Medicine - April 8, 2020 Category: Cardiology Tags: Rev Cardiovasc Med Source Type: research

Ticagrelor: clinical development and future potential
Rev Cardiovasc Med. 2021 Jun 30;22(2):373-394. doi: 10.31083/j.rcm2202044.ABSTRACTPlatelets participate centrally in atherothrombosis, resulting in vessel occlusion and ischaemia. Consequently, optimisation of antiplatelet regimens has the potential to further reduce the residual burden of morbidity and mortality associated with atherosclerosis. Ticagrelor is a potent oral platelet P2Y12 receptor antagonist that (1) inhibits a central amplification pathway of platelet activation directly as well as via an active metabolite, (2) has a rapid onset and offset of antiplatelet action that remains consistent in the circulation d...
Source: Reviews in Cardiovascular Medicine - July 14, 2021 Category: Cardiology Authors: Nicholas C Sanderson William A E Parker Robert F Storey Source Type: research

Pages: 1  2  3  4